Vicore reports data from EndoPAT® exploratory trial
Stockholm, August 22, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today reports that its clinical study investigating the EndoPAT® technology as a tool to assess the effect of C21 on endothelial function is complete and that the data were inconclusive.
- Purpose was to test the utility of the EndoPAT® technology to study pharmacological vasodilation
- Results were inconclusive due to high intra-individual variability
